Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Engineers Gate Manager LP

Engineers Gate Manager LP decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 78.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 540 shares of the biopharmaceutical company’s stock after selling 1,986 shares during the period. Engineers Gate Manager LP’s holdings in Regeneron Pharmaceuticals were worth $372,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Riggs Asset Managment Co. Inc. raised its position in shares of Regeneron Pharmaceuticals by 15.0% in the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 115 shares of the biopharmaceutical company’s stock valued at $79,000 after purchasing an additional 15 shares in the last quarter. Moody National Bank Trust Division raised its holdings in Regeneron Pharmaceuticals by 1.4% in the third quarter. Moody National Bank Trust Division now owns 1,130 shares of the biopharmaceutical company’s stock valued at $778,000 after acquiring an additional 16 shares in the last quarter. Anderson Hoagland & Co. boosted its stake in Regeneron Pharmaceuticals by 0.4% during the 3rd quarter. Anderson Hoagland & Co. now owns 4,520 shares of the biopharmaceutical company’s stock valued at $3,114,000 after acquiring an additional 16 shares during the last quarter. Plancorp LLC grew its holdings in Regeneron Pharmaceuticals by 0.8% during the 1st quarter. Plancorp LLC now owns 2,276 shares of the biopharmaceutical company’s stock worth $1,590,000 after acquiring an additional 17 shares in the last quarter. Finally, Janiczek Wealth Management LLC grew its holdings in Regeneron Pharmaceuticals by 16.8% during the 3rd quarter. Janiczek Wealth Management LLC now owns 118 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 17 shares in the last quarter. Hedge funds and other institutional investors own 84.25% of the company’s stock.

Insiders Place Their Bets

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $762.50, for a total transaction of $76,250.00. Following the completion of the sale, the director now owns 19,147 shares in the company, valued at approximately $14,599,587.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director N Anthony Coles sold 5,758 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, December 28th. The stock was sold at an average price of $714.11, for a total value of $4,111,845.38. Following the transaction, the director now owns 1,093 shares of the company’s stock, valued at approximately $780,522.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $762.50, for a total transaction of $76,250.00. Following the sale, the director now directly owns 19,147 shares of the company’s stock, valued at $14,599,587.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 27,273 shares of company stock worth $21,189,979. 8.99% of the stock is owned by insiders.

Regeneron Pharmaceuticals Trading Up 0.7 %

Shares of Regeneron Pharmaceuticals stock opened at $752.33 on Tuesday. The business has a fifty day simple moving average of $744.30 and a 200-day simple moving average of $725.99. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $538.01 and a fifty-two week high of $800.48. The firm has a market cap of $82.25 billion, a price-to-earnings ratio of 19.67, a price-to-earnings-growth ratio of 2.57 and a beta of 0.21. The company has a quick ratio of 4.29, a current ratio of 5.06 and a debt-to-equity ratio of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last issued its quarterly earnings results on Friday, February 3rd. The biopharmaceutical company reported $12.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.18 by $4.38. Regeneron Pharmaceuticals had a net margin of 35.64% and a return on equity of 22.87%. The company had revenue of $3.41 billion during the quarter, compared to the consensus estimate of $3.11 billion. During the same period in the prior year, the company earned $23.72 EPS. Regeneron Pharmaceuticals’s revenue was down 31.1% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 34.22 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on REGN shares. Cowen raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $775.00 to $875.00 in a research report on Monday, January 30th. Cowen raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $775.00 to $875.00 in a report on Monday, January 30th. Wells Fargo & Company upped their price target on Regeneron Pharmaceuticals from $800.00 to $860.00 and gave the company an “overweight” rating in a research report on Friday, February 17th. StockNews.com raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, February 23rd. Finally, EF Hutton Acquisition Co. I reissued a “buy” rating and set a $853.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, February 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $804.10.

About Regeneron Pharmaceuticals

(Get Rating)

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.